Long-Term Treatment with Atypical Antipsychotics and the Risk of Weight Gain
- 1 January 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 29 (4), 303-319
- https://doi.org/10.2165/00002018-200629040-00002
Abstract
The aim of this review is to analyse and summarise the literature data about the incidence of weight gain in patients exposed to atypical antipsychotics during long-term (≥1 year) treatment regimens. Despite the clinical relevance of the topic, the vast majority of reviewed studies showed methodological limitations. Some trials had retrospective analysis, and concomitant medications also associated with an increased risk of weight gain, such as antidepressants and mood stabilisers, were often prescribed. Results were obtained from clinical trials conducted using flexible dosages; thus, the relationship between dosage and weight change was not explored adequately. Also, in a large number of studies, the average antipsychotic daily dose was lower than the usual dosage in clinical practice. Moreover, weight gain was evaluated by different measures, such as mean weight gain in the enrolled population, percentage of patients who gained >7% of basal weight or body mass index (BMI) variations from baseline. In short-term studies, a definite rank order of weight-gain potential among atypical antipsychotics has been demonstrated: clozapine is related to the highest risk of weight gain, followed in decreasing order of magnitude by olanzapine, quetiapine, risperidone, amisulpride, aripiprazole and ziprasidone. However, in long-term studies, except for clozapine at one end of the scale and ziprasidone at the other, the differences in weight-gain liability showed by the other atypical antipsychotics became less intense. Differences between short-term and long-term treatment could be due to a complex overlapping of different factors, both drug-specific (relative receptorial affinity; timing of weight change plateau; and drug-specific/dose-dependent weight gain), and patient-specific (genetic vulnerability; sex; age; BMI; weight before starting antipsychotic treatment; type of psychiatric disorder; and individual lifestyle). There is an urgent need for well designed, randomised controlled trials to assess firmly both the differential effects of atypical antipsychotics on weight and the role of other factors in contributing to iatrogenic unwanted weight changes. Meanwhile, the well known benefits shown by some atypical antipsychotics in reducing akathisia and other extrapyramidal adverse effects and improving cognition should be carefully balanced with the problems of weight gain, other metabolic complications and higher healthcare costs.Keywords
This publication has 134 references indexed in Scilit:
- Clinical review of a long-acting, injectable formulation of risperidoneClinical Therapeutics, 2004
- Effects on Weight and Outcome of Long-term Olanzapine-Topiramate Combination Treatment in Bipolar DisorderJournal of Clinical Psychopharmacology, 2004
- Impaired Fasting Glucose Tolerance in First-Episode, Drug-Naive Patients With SchizophreniaAmerican Journal of Psychiatry, 2003
- AripiprazoleCNS Drugs, 2002
- The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophreniaInternational Journal of Psychiatry in Clinical Practice, 2000
- Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trialInternational Journal of Neuropsychopharmacology, 1999
- Randomised controlled trial of compliance therapyThe British Journal of Psychiatry, 1998
- QuetiapineCNS Drugs, 1998
- Determinants of Medication Compliance in Schizophrenia: Empirical and Clinical FindingsSchizophrenia Bulletin, 1997
- Feeding induced by blockade of histamine H1-receptor in rat brainCellular and Molecular Life Sciences, 1988